<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01957943</url>
  </required_header>
  <id_info>
    <org_study_id>LTX_SMOF_PRE_Eg</org_study_id>
    <nct_id>NCT01957943</nct_id>
  </id_info>
  <brief_title>Omega 3 Lipid Emulsions and Liver Transplantation</brief_title>
  <acronym>OTLT</acronym>
  <official_title>Impact of Pre-treatment of Living-donor Liver Transplant Recipients With Omega 3 Enriched Lipid Emulsions on Graft and Patient Outcome. A Prospective, Randomized, Multi-central Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mansoura University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mansoura University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study Aims to investigate the possible beneficial impact of peri-operative or
      post-operative administration of Omega 3 enriched lipid emulsions on recipients for living
      donor liver transplantation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will be divided intro three groups, A control group will receive equivalent volume
      of glucose 10% solution both 3 days before and 5 days after the operation .

      A peri-operative groups, in which patients will receive omega 3 enriched lipid emulsion
      (SMOFLipid) for 2 days pre-transplantation and 5 days post-transplantation A Post-operative
      group, in which patients will receive glucose 10% 3 days before the operation and omega 3
      enriched lipid emulsion (SMOFLipid) for 5 days post-transplantation The primary outcome
      objective will be the incidence of Ischemia re-perfusion injury, secondary outcomes includes
      post-operative complications, graft and patient's outcomes and graft regeneration
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Anticipated">March 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ischemia reperfusion injury</measure>
    <time_frame>5 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Liver functions</measure>
    <time_frame>5 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Early graft regeneration</measure>
    <time_frame>one month</time_frame>
    <description>assessment of percent of liver regeneration 1 month PO</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Late graft regeneration</measure>
    <time_frame>3 month</time_frame>
    <description>assessment of percent of liver regeneration 13 months PO</description>
  </secondary_outcome>
  <other_outcome>
    <measure>mortality</measure>
    <time_frame>28 days</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Renal functions</measure>
    <time_frame>28 days</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Infection</measure>
    <time_frame>28 days</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>length of hospital stay</measure>
    <time_frame>30 days</time_frame>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">114</enrollment>
  <condition>Ischemia Re-perfusion Injury</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>38 patients Will receive standard oral diet 3 days before the operation will receive similar volume of 10% glucose solution Will receive same solution for 5 days postoperatively</description>
  </arm_group>
  <arm_group>
    <arm_group_label>OMEGA_PRE</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>38 patients Will receive standard oral diet 3 days before the operation will receive lipid supplementation 2 days before the operation with omega 3 enriched lipid emulsion (SMOFlipid) Will receive omega 3 enriched lipid emulsion (SMOFlipid) supplementation for 5 days postoperatively</description>
  </arm_group>
  <arm_group>
    <arm_group_label>OMEGA_POST</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>38 patients Will receive standard oral diet 3 days before the operation will receive glucose 10% solution 2 days before the operation Will receive omega 3 enriched lipid emulsion (SMOFlipid 20%) supplementation for 5 days postoperatively</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>SMOFLipid</intervention_name>
    <arm_group_label>OMEGA_PRE</arm_group_label>
    <arm_group_label>OMEGA_POST</arm_group_label>
    <other_name>Omega 3 lipid emulsions</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>equivalent volume of 10% glucose solution</intervention_name>
    <description>Patients will receive same dose of 10% glucose solution for 2 days pre operatives and 5 days post-operative</description>
    <arm_group_label>Control</arm_group_label>
    <other_name>control group</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All liver transplant recipients

        Exclusion Criteria:

          -  Budd chiari

          -  Previous upper abdominal surgery

          -  Re-transplantation

          -  Known allergy to the study emulsion
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Amr M Yassen, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Mansoura University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Amr M Yassen, Md</last_name>
    <phone>+201001497044</phone>
    <email>amryassen@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Waleed R Elsarraf, MD</last_name>
    <phone>+201222322727</phone>
    <email>welsarraf@yahoo.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Liver transplantation program - Gastroenterology surgical center - Mansoura university</name>
      <address>
        <city>Mansoura</city>
        <state>Dakahlia</state>
        <zip>35511</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amr M Yassen, MD</last_name>
      <phone>+201001497044</phone>
      <email>amryassen@hotmail.com</email>
    </contact>
    <contact_backup>
      <last_name>waleed R elsarraf, MD</last_name>
      <phone>+201222322727</phone>
      <email>welsarraf@gmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 4, 2013</study_first_submitted>
  <study_first_submitted_qc>October 4, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 8, 2013</study_first_posted>
  <last_update_submitted>March 24, 2017</last_update_submitted>
  <last_update_submitted_qc>March 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mansoura University</investigator_affiliation>
    <investigator_full_name>Amr Mohamed Yassen</investigator_full_name>
    <investigator_title>Professor Doctor Amr M. Yassen</investigator_title>
  </responsible_party>
  <keyword>Omega 3 lipid emulsions</keyword>
  <keyword>Liver transplantation</keyword>
  <keyword>Ischemia reperfusion injury</keyword>
  <keyword>graft function</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Reperfusion Injury</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

